Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects
Dougal R. McClean(Christchurch Hospital), James Hanyok(Daiichi Sankyo (United States)), Benoit Coutu(Hôpital Notre-Dame), Chunlin Qian(Bristol-Myers Squibb (United States)), Sukh S. Mehta, Michel Komajda(Hôpital Saint Joseph), Peter Hanrath(Universitätsklinikum Aachen), Eckart Fleck(Deutsches Herzzentrum der Charité), Rafael F. Sequeira(University of Miami), Catherine Bryson(Bristol-Myers Squibb (United States)), J. Thomas Heywood(Jerry L. Pettis Memorial VA Medical Center), Steven Singh(United States Department of Veterans Affairs), Hamid Ikram(Christchurch Hospital), Alan Niederman, Michel F. Rousseau(Cliniques Universitaires Saint-Luc)
Cited by 36
Related Papers
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment
|European Heart Journal|2003|1.2k
State of the Art: Using Natriuretic Peptide Levels in Clinical Practice
|European Journal of Heart Failure|2008|837